Health Trials

Pulmonary Hypertension Associated With HFpEF

2

Review clinical trials related to Pulmonary Hypertension Associated With HFpEF. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Percutaneous Pulmonary Artery Denervation (PADN) for the Treatment of Pulmonary Hypertension After Transcatheter Mitral Valve Edge-to-Edge Repair (M-TEER): A Prospective Cohort Study

this study aims to investigate the efficacy and safety of PADN therapy compared with standard medical therapy in patients diagnosed with pulmonary hypertension after M-TEER, thereby providing evidence for clinical treatment decision-making

Participants needed: 60
Trial details
Phase: Early Phase 1Age: 18-80Biological sex: AllType: InterventionalSponsor: Xiamen Cardiovascular Hospital, Xiamen UniversityUpdated: Jun 23, 2026Locations: 1
Eligibility criteria

Age ≥18 years and ≤80 years; [+4]

Cardiac index (CI) < 1.5 L/min/m²; [+15]

Read more
Status: Recruiting

LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2

The purpose of this study is to assess the efficacy and safety of the study drug, levosimendan (given orally), compared to placebo in participants with pulmonary hypertension with heart failure with preserved left ventricular ejection fraction (PH-HFpEF) as measured by the change in 6-Minute Walk Distance.

Participants needed: 540
Trial details
Phase: Phase 3Age: 18-85Biological sex: AllType: InterventionalSponsor: Tenax Therapeutics, Inc.Updated: Mar 16, 2026Locations: 92
Eligibility criteria

Men or women, ≥18 to 85 years of age [+7]

A diagnosis of PH WHO Groups 1, 3, 4, or 5 [+7]

Read more